Vaccine Analysis: Strategies, Principles, and Control

Nunnally, Brian K.; Turula, Vincent E.; Sitrin, Robert D.

doi:10.1007/978-3-662-45024-6

Cited by 31 publications

(5 citation statements)

References 427 publications

(547 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Formaldehyde inactivation continues to be used more extensively in vaccines today. Poliovirus (PV), hepatitis A virus (HAV), Japanese encephalitis virus (JEV), tick borne encephalitis virus (TBEV), rabies virus, and influenza virus each have licensed inactivated vaccines produced from formaldehyde inactivated particles (Sanders et al, 2015). Vaccines for viruses inactivated with UV irradiation have been proven to be effective in producing virus-specific immune responses for murine leukemia virus strain Cas-Br-M (UV-Cas) (Sarzotti et al, 1994) and porcine reproductive and respiratory syndrome virus (PRRSV) (Vanhee et al, 2009), but this was not the case with the UV-inactivated vaccine for rabbit hemorrhagic disease virus (RHDV) (Henning et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Full inactivation of alphaviruses in single particle and crystallized forms

Lawrence¹,

Zook²,

Hogue

2016

Journal of Virological Methods

View full text Add to dashboard Cite

Inherent in the study of viruses is the risk of pathogenic exposure, which necessitates appropriate levels of biosafety containment. Unfortunately, this also limits the availability of useful research instruments that are located at facilities not equipped to handle infectious pathogens. Abrogation of viral infectivity can be accomplished without severely disrupting the physical structure of the virus particle. Virus samples that are verifiably intact but not infectious may be enabled for study at research facilities where they would otherwise not be allowed. Inactivated viruses are also used in the development of vaccines, where immunogenicity is sought in the absence of active infection. We demonstrate the inactivation of Sindbis alphavirus particles in solution, as well as in crystallized form. Inactivation was accomplished by two different approaches: crosslinking of proteins by glutaraldehyde treatment, and crosslinking of nucleic acids by UV irradiation. Biophysical characterization methods, including dynamic light scattering and transmission electron microscopy, were used to demonstrate that the glutaraldehyde and UV inactivated Sindbis virus particles remain intact structurally. SDS-PAGE was also used to show evidence of the protein crosslinking that was expected with glutaraldehyde treatment, but also observed with UV irradiation.

show abstract

Section: Discussionmentioning

confidence: 99%

Full inactivation of alphaviruses in single particle and crystallized forms

Lawrence¹,

Zook²,

Hogue

2016

Journal of Virological Methods

View full text Add to dashboard Cite

show abstract

“…The zoster vaccine is a new, adjuvanted, non-live recombinant shingles vaccine, without the capacity to produce the disease, making it less reactogenic [2]. Thus, a weaker immune response is created, and a subsequent booster injection is typically required to establish immunogenicity [3,4]. Contraindications for the vaccine include a history of severe allergic reactions (e.g., anaphylaxis) to any vaccine or vaccine component, current shingles infection, and pregnancy [1,5].…”

Section: Introductionmentioning

confidence: 99%

A Case Report of Shingles Vaccine as a Cause of Third Nerve Palsy: A Novel Etiology

Sanchez,

DeLosSantos,

Dandamudi

et al. 2024

Cureus

View full text Add to dashboard Cite

Vaccines are biological preparations widely used to provide acquired immunity against various life-threatening organisms and prevent severe complications of different infections. Vaccines typically demonstrate a high level of safety with minimal adverse effects. Nevertheless, it is crucial to enhance awareness when a potential new side effect emerges, as exemplified in the case discussed ahead. Despite the rarity of independent third nerve palsy occurrences, its association with the zoster vaccine remains unprecedented.

show abstract

“…For example, if a downstream release method were to be updated to be more precise, this would allow room for greater variability in the upstream product manufacture process while still resulting in the same total (process + analytical) variability. Since this update in the testing method could lead to an unacceptable product change, analytical changes will require a holistic view and approach. , In addition, the release methods are also deployed globally as regulatory agencies in many countries carry out their own release testing upon importation of vaccines. Therefore, these methods should meet a set of stringent requirements, including affordability, robustness, and simplicity with respect to equipment, operational procedures, and requirement of trained personnel.…”

Section: Introductionmentioning

confidence: 99%

Development of an Aptamer-Based Electrochemical Microfluidic Device for Viral Vaccine Quantitation

et al. 2022

View full text Add to dashboard Cite

Global deployment of vaccines poses significant challenges in the distribution and use of the accompanying immunoassays, one of the standard methods for quality control of vaccines, particularly when establishing assays in countries worldwide to support testing/release upon importation. This work describes our effort toward developing an integrated, portable device to carry out affinity assays for viral particles quantification in viral vaccines by incorporating (i) aptamers, (ii) microfluidic devices, and (iii) electrochemical detection. We generated and characterized more than eight aptamers against multiple membrane proteins of cytomegalovirus (CMV), which we used as a model system and designed and fabricated electrochemical microfluidic devices to measure CMV concentrations in a candidate vaccine under development. The aptamer-based assays provided a half maximal effective concentration, EC 50 , of 12 U/mL, comparable to that of an ELISA using a pair of antibodies (EC 50 60 U/mL). The device measured relative CMV concentrations accurately (within ±10% bias) and precisely (11%, percent relative standard deviation). This work represents the critical first steps toward developing simple, affordable, and robust affinity assays for global deployment without the need for sensitive equipment and extensive analyst training.

show abstract

Vaccine Analysis: Strategies, Principles, and Control

Cited by 31 publications

References 427 publications

Full inactivation of alphaviruses in single particle and crystallized forms

Full inactivation of alphaviruses in single particle and crystallized forms

A Case Report of Shingles Vaccine as a Cause of Third Nerve Palsy: A Novel Etiology

Development of an Aptamer-Based Electrochemical Microfluidic Device for Viral Vaccine Quantitation

Contact Info

Product

Resources

About